{"prompt": "['CONFIDENTIAL', '204878 (ZOSTER-064)', 'Protocol Administrative Change 3 Final', 'This should help confirm previously hypothesized predictive', 'factors such as age, stress or functional status, and also to', 'assess other potential risk factors such as frailty, fatigue or', 'emotional and mental health.', 'Study design', 'A multi-country, observational, retrospective study.', 'Study population: All subjects enrolled in ZOSTER-006', 'and ZOSTER-022.', 'Type of study: Data to be analysed in this study have', 'been collected in the ZOSTER-006 (eTrack 110390) and', 'ZOSTER-022 (eTrack 113077) and will be combined for', 'assessment of primary, secondary and tertiary objectives.', 'Data collection: QoL questionnaires and the year of birth', 'of subjects enrolled in ZOSTER-006 and ZOSTER-022.', '-', 'QoL questionnaires: The SF-36 is a multi-purpose', 'health survey with 36 questions. The EQ-5D is a', 'questionnaire with 5 questions designed as a generic', 'measure of health status that provides a simple', 'descriptive profile and a single index value. The EQ-', '5D defines health in terms of mobility, self-care,', 'usual activities, pain/discomfort and', 'anxiety/depression.', 'Method: Frailty scores for study subjects in ZOSTER-006', 'and ZOSTER-022 will be calculated by incorporating the', \"subject's medical history and items from the SF-36 and\", 'EQ-5D questionnaires.', 'Discussion of study', 'This is a retrospective, observational study of subjects', 'design', 'previously enrolled in ZOSTER-006 and ZOSTER-022,', 'therefore no new subjects will be enrolled in this study and no', 'new ICF will be required from study subjects.', 'Number of subjects', 'Approximately 30,000 subjects who were enrolled in', 'ZOSTER-006 and ZOSTER-022', 'Enppoints', 'Primary', 'Baseline Frailty Status:', '-', 'Frailty Status pre-vaccination dose 1 as defined by', 'responses to components of the SF-36 and EQ-5D', 'questionnaire at vaccination day 0 and the subjects', 'coded medical history.', '11-FEB-2019', '10', '70882527ffe6806e42bab9a20b06541da11028ce']['CONFIDENTIAL', '204878 (ZOSTER-064)', 'Protocol Administrative Change 3 Final', 'Secondary', 'SF-36 and EQ-5D scale scores:', '-', 'At months 0, 14, 26 and 38.', 'Confirmed HZ cases:', '-', 'Incidence of HZ cases during ZOSTER-006 and', 'ZOSTER-022 for subjects in the modified Total', 'Vaccinated Cohort (mTVC).', 'HZ Burden of Illness:', '-', 'HZ Burden of Illness score for subjects in both', 'ZOSTER-006 and ZOSTER-022 as calculated from', 'the Zoster Brief Pain Inventory (ZBPI).', 'Solicited local and general symptoms from ZOSTER-006', 'and ZOSTER-022:', '-', 'Occurrence, intensity of each solicited local', 'symptom within 7 days (Days 0-6) after each', 'vaccination, in subjects included in the 7-day diary', 'card subset;', '-', 'Occurrence, intensity and relationship to vaccination', 'of each solicited general symptom within 7 days', '(Days 0-6) after each vaccination, in subjects', 'included in the 7-day diary card subset.', 'Unsolicited adverse events (AEs) from ZOSTER-006 and', 'ZOSTER-022:', '-', 'Occurrence, intensity and relationship to vaccination', 'of unsolicited AEs during 30 days (Days 0 - 29) after', 'each vaccination, according to the Medical', 'Dictionary for Regulatory Activities (MedDRA)', 'classification in all subjects.', 'Serious Adverse Events (SAEs) from ZOSTER-006 and', 'ZOSTER-022.', '- Occurrence and relationship to vaccination of all', 'SAEs from Month 0 to Month 14 in all subjects;', '-', 'Occurrence of SAEs related to study participation or', 'to a concurrent GSK medication/vaccine during the', 'entire study period in all subjects;', '-', 'Occurrence of any fatal SAEs during the entire study', 'period in all subjects.', '11-FEB-2019', '11', '70882527ffe6806e42bab9a20b06541da11028ce']\n\n###\n\n", "completion": "END"}